[go: up one dir, main page]

MX2015014198A - Anticuerpos cuyo objetivo es m-csf. - Google Patents

Anticuerpos cuyo objetivo es m-csf.

Info

Publication number
MX2015014198A
MX2015014198A MX2015014198A MX2015014198A MX2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A MX 2015014198 A MX2015014198 A MX 2015014198A
Authority
MX
Mexico
Prior art keywords
csf
antibodies
fragments
antibodies targeting
antibody fragments
Prior art date
Application number
MX2015014198A
Other languages
English (en)
Inventor
Francis Dodeller
Robert Rauchenberger
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2015014198A publication Critical patent/MX2015014198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Esta divulgación se refiere, en general, a anticuerpos o fragmentos de anticuerpos que se unen específicamente a M-CSF. En particular, se divulgan anticuerpos y fragmentos de anticuerpos que se unen a M-CSF y que inhiben la unión de M-CSF al receptor de M-CSF con una CI50 igual o inferior a 10 pM. La invención también se refiere a ácidos nucleicos, vectores y células hospedadoras capaces de expresar los anticuerpos o fragmentos de estos de la invención, composiciones farmacéuticas que comprenden los anticuerpos o fragmentos de estos y los usos de dichos anticuerpos o fragmentos de estos y composiciones para el tratamiento de enfermedades específicas.
MX2015014198A 2013-04-12 2014-04-11 Anticuerpos cuyo objetivo es m-csf. MX2015014198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13163542 2013-04-12
PCT/EP2014/057360 WO2014167088A1 (en) 2013-04-12 2014-04-11 Antibodies targeting m-csf

Publications (1)

Publication Number Publication Date
MX2015014198A true MX2015014198A (es) 2015-12-11

Family

ID=48050609

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014198A MX2015014198A (es) 2013-04-12 2014-04-11 Anticuerpos cuyo objetivo es m-csf.

Country Status (13)

Country Link
US (2) US9856316B2 (es)
EP (1) EP2984106B1 (es)
JP (1) JP2016516092A (es)
KR (1) KR20150140752A (es)
CN (1) CN105121466A (es)
AU (1) AU2014253090B2 (es)
BR (1) BR112015025622A2 (es)
CA (1) CA2907973A1 (es)
EA (1) EA031471B1 (es)
MX (1) MX2015014198A (es)
SG (1) SG11201507871XA (es)
WO (1) WO2014167088A1 (es)
ZA (1) ZA201507251B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10800846B2 (en) 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
CN115806626B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141290T1 (de) 1989-02-10 1996-08-15 Cetus Oncology Corp M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
CA2304354A1 (en) 1997-10-02 1999-04-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60041119D1 (de) 1999-07-20 2009-01-29 Morphosys Ag Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
EP1223980B1 (de) 1999-10-28 2003-05-21 Hofbauer, Reinhold Verwendung von csf-1-inhibitoren
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
PL374506A1 (en) 2001-10-15 2005-10-31 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
SE0200667D0 (sv) 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
US20110091451A1 (en) 2002-11-15 2011-04-21 Kavanaugh William M Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AU2003291002A1 (en) 2002-11-15 2004-06-15 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
RU2401277C2 (ru) 2004-01-07 2010-10-10 Чирон Корпорейшн Не мышиное анти-m-csf-антитело (варианты), его получение и использование
JP2006249083A (ja) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 抗ｍ−ｃｓｆ抗体組成物
WO2007011896A2 (en) 2005-07-18 2007-01-25 The Trustees Of Boston University Method to inhibit proliferation and growth of metastases
JP5657862B2 (ja) * 2005-07-28 2015-01-21 ノバルティス アーゲー Ｍ−ｃｓｆに対する抗体の使用
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
EP1984024A2 (en) 2006-01-05 2008-10-29 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20090010941A1 (en) 2007-04-09 2009-01-08 University Of Massachusetts Methods for treating HIV
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
GB0725217D0 (en) 2007-12-24 2008-02-06 Reckitt Benckiser Uk Ltd Cleaning device
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2010017224A2 (en) 2008-08-05 2010-02-11 University Of South Florida Methods of treating cognitive impairment
HUE044179T2 (hu) 2009-12-10 2019-10-28 Hoffmann La Roche Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
BR112014011115A2 (pt) 2011-11-08 2017-06-13 Pfizer métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf

Also Published As

Publication number Publication date
JP2016516092A (ja) 2016-06-02
EP2984106A1 (en) 2016-02-17
EA201591898A1 (ru) 2016-03-31
BR112015025622A2 (pt) 2017-07-18
US20160102142A1 (en) 2016-04-14
CN105121466A (zh) 2015-12-02
US10081675B2 (en) 2018-09-25
EP2984106B1 (en) 2019-03-06
EA031471B1 (ru) 2019-01-31
WO2014167088A1 (en) 2014-10-16
CA2907973A1 (en) 2014-10-16
US9856316B2 (en) 2018-01-02
ZA201507251B (en) 2016-12-21
US20180057581A1 (en) 2018-03-01
AU2014253090A1 (en) 2015-10-08
AU2014253090B2 (en) 2018-10-25
SG11201507871XA (en) 2015-10-29
KR20150140752A (ko) 2015-12-16

Similar Documents

Publication Publication Date Title
ZA202308846B (en) Cx3cr1-binding polypeptides
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
MX359258B (es) Polipeptidos de enlace biparatopicos para cxcr2 y usos de los mismos.
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2015109124A3 (en) Immunomodulatory agents
NZ717399A (en) Antibodies against csf-1r
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
HK1215868A1 (zh) 双特异性构建体及其用於治疗多种疾病的用途
WO2014163714A3 (en) Antibody drug conjugates
NZ710929A (en) Antibody drug conjugates
WO2016063026A3 (en) Selective nav protein binders
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
NZ700274A (en) Anti-pdgf-c antibodies
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
HK1196856A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения
HK1196831A (en) Lsr antibodies, and uses thereof for treatment of cancer
TN2013000171A1 (en) Cxcr2 binding polypeptides